X

Trial Profile

Long-term tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
Indications Rheumatoid arthritis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms GROWTH96

Most Recent Events

30 Oct 2013 Tolerability results from a pooled analysis presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
26 Nov 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com